| Title | Botulinum toxin type a intralesional monotherapy for treating human hypertrophic scar in a dose-dependent manner: In an animal model |
| Authors | Li, Yawei Shan, Xiaofeng Mao, Qianying Xiang, Ruolan Cai, Zhigang |
| Affiliation | Peking Univ, Sch & Hosp Stomatol, Natl Engn Lab Digital & Mat Technol Stomatol, Dept Oral & Maxillofacial Surg, Beijing 100081, Peoples R China Peking Univ, Sch Basic Med Sci, Dept Physiol & Pathophysiol, Beijing 100191, Peoples R China |
| Keywords | GROWTH-FACTOR-BETA KELOID SCARS DOUBLE-BLIND INJECTION TRIAMCINOLONE ACETONIDE EFFICACY DECORIN SAFETY MOUSE |
| Issue Date | Nov-2021 |
| Publisher | JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY |
| Abstract | Background: The effect of Botulinum toxin type A (BTX-A) in treating or preventing a hypertrophic scar (HS) had been reported in clinical studies. However, the dose-effect relationship remains unclear. Objective: To study the dose-effect relationship of BTX-A intralesional monotherapy treating human HS. Methods: Six HS tissues were collected from six patients. Each tissue was segmented into 24 specimens and split into four groups: negative control (group A), 0.5U BTX-A (group B), 1U BTX-A (group C), and 2U BTX-A (group D). Six nude mice, each was prepared by implanting four specimens (one from each group) into the back for a total of 24 specimens. The process mentioned above were repeated six times. A re-entry operation was performed to obtain the specimens after 8 weeks. The weight of HS, the expression of decorin and TGF-beta(1), the proliferation, and migration ability of hypertrophic scar fibroblasts (HSFBs) were compared among groups. Results: The weight of HS, the expression of decorin and TGF-beta(1), the proliferation, and migration ability of HSFBs showed significant differences in groups C and D as compared to group A; there has been no statistical significance in group B. Conclusion: BTX-A showed significant therapeutic efficacy when compared with the negative control group in a dose-dependent manner. BTX-A can reduce the weight of HS, upregulate the expression of decorin, downregulate the expression of TGF- beta(1), and inhibit HSFBs proliferation and migration ability. This study indicates that BTX-A intralesional monotherapy treating HS should reach a threshold dose to achieve an effective treatment, and a high dose of BTX-A is more effective than a low dose. (C) 2021 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved. |
| URI | http://hdl.handle.net/20.500.11897/629123 |
| ISSN | 1748-6815 |
| DOI | 10.1016/j.bjps.2021.03.062 |
| Indexed | SCI(E) |
| Appears in Collections: | 口腔医院 基础医学院 |
